Immuneering Corporation (IMRX) - News Archive

Pancreatic cancer remains one of the most formidable challenges in oncology, characterized by its aggressive nature and high mortality rates. In recent years, innovation in therapeutic strategies has gained momentum, wi...

Immuneering s Bold Move in Pancreatic Cancer Treatment Amid Financial ChallengesIn a high-stakes environment where the pharmaceutical industry is often fraught with both promise and peril, Immuneering Corporation s rece...

Immuneering s Significant Milestone: Orphan Drug Designation for IMM-1-104 in the Fight Against Pancreatic Cancer In a notable advancement for the treatment of one of the most aggressive forms of cancer, Immuneering Cor...

In a remarkable stride towards transforming pancreatic cancer therapies, Immuneering Corporation has unveiled positive initial data from its Phase 2a clinical trial of IMM-1-104. This investigational agent, in synergy w...

In a significant development for the treatment of pancreatic cancer, Immuneering Corporation has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its investigational drug, IMM-1-104....

Immuneering, a biopharmaceutical company focused on developing innovative treatments for cancer, recently announced a significant milestone in its quest to combat advanced solid tumors with RAF or RAS mutations. The com...

In the world of pharmaceutical sciences, groundbreaking clinical trials often set the stage for the development of revolutionary therapies. Recent positive topline results from the phase 1 portion of Immuneering s phase...

In an exciting development for Immuneering Corporation, a leading player in the field of biomedicine, the company has announced the appointment of Dr. Thomas J. Schall to its Board of Directors. Dr. Schall, the former C...

In a groundbreaking move, Immuneering recently commenced its Phase 2a clinical trial for its innovative drug candidate, IMM-1-104, targeting RAS-mutant solid tumors. Furthermore, the company achieved an important milest...

In a breakthrough development for Immuneering, the company has recently been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for their lead asset IMM-1-104 in the treatment of pancreatic du...

Biopharmaceutical company Immuneering Corporation recently announced the United States Food and Drug Administration’s (FDA) clearance of their Investigational New Drug (IND) application. This landmark approval gives Imm...